Aclaris Therapeutics Inc (NASDAQ: ACRS) kicked off on Monday, down -4.14%% from the previous trading day, before settling in for the closing price of $1.45. Over the past 52 weeks, ACRS has traded in a range of $1.05-$5.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 15.24%. While this was happening, its average annual earnings per share was recorded 67.20%. With a float of $92.25 million, this company’s outstanding shares have now reached $108.27 million.
Let’s determine the extent of company efficiency that accounts for 64 employees. In terms of profitability, gross margin is 20.55%, operating margin of -791.9%, and the pretax margin is -732.42%.
Aclaris Therapeutics Inc (ACRS) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Aclaris Therapeutics Inc is 14.81%, while institutional ownership is 75.05%. The most recent insider transaction that took place on Nov 19 ’24, was worth 1,499,998. In this transaction Director of this company bought 666,666 shares at a rate of $2.25, taking the stock ownership to the 710,030 shares. Before that another transaction happened on Aug 05 ’24, when Company’s 10% Owner bought 206,025 for $1.24, making the entire transaction worth $256,357. This insider now owns 14,250,000 shares in total.
Aclaris Therapeutics Inc (ACRS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 67.20% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.55% during the next five years compared to 15.24% growth over the previous five years of trading.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
Take a look at Aclaris Therapeutics Inc’s (ACRS) current performance indicators. Last quarter, stock had a quick ratio of 5.06. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.40, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.64 in one year’s time.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
Looking closely at Aclaris Therapeutics Inc (NASDAQ: ACRS), its last 5-days average volume was 0.85 million, which is a jump from its year-to-date volume of 0.85 million. As of the previous 9 days, the stock’s Stochastic %D was 24.85%.
During the past 100 days, Aclaris Therapeutics Inc’s (ACRS) raw stochastic average was set at 21.94%, which indicates a significant increase from 16.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.36% in the past 14 days, which was lower than the 65.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3324, while its 200-day Moving Average is $1.9288. However, in the short run, Aclaris Therapeutics Inc’s stock first resistance to watch stands at $1.4533. Second resistance stands at $1.5167. The third major resistance level sits at $1.5733. If the price goes on to break the first support level at $1.3333, it is likely to go to the next support level at $1.2767. Should the price break the second support level, the third support level stands at $1.2133.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Key Stats
The company with the Market Capitalisation of 150.51 million has total of 108,281K Shares Outstanding. Its annual sales at the moment are 18,720 K in contrast with the sum of -132,070 K annual income. Company’s last quarter sales were recorded 1,460 K and last quarter income was -15,090 K.
